Abstract
About this talk
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. The primary prevention of CVD is dependent upon the ability to identify high-risk individuals long before the development of overt events. This highlights the need for accurate risk stratification.
For a number of years healthcare professionals have been using a wide range of traditional methods and tools for assessing and calculating individual’s predicted future risk for cardiovascular disease including coronary and cerebrovascular disease. They include taking into account presence of co-morbidities such as Diabetes Mellitus, Hypertension, Dyslipidaemia, smoking and family history. Risk scoring tools such as Framingham and Risk score and also utilization of some basic cardiac investigations. These methods have been useful but we realise that they always do not adequately and accurately predict the cardiovascular risk.
Critical evaluation of risk markers and risk assessment methods have become even more important as novel markers of cardiovascular risk are identified by technological advances in genetics, genomics, proteomics, and non-invasive imaging. They have been shown to evaluate the risk of an individual in more depth than the traditional methods and perhaps also provide insights into the unexplored and hidden risks.
However, these novel methods of cardiovascular risk assessments are costly and not readily available and hence they must be judiciously utilised to provide a more individualized and personalised approach so that this strategy is more cost effective.
Speaker
About the speaker

